lenalidomide maintenance in patients with primary central nervous system lymphoma
Not Applicable
Not yet recruiting
- Conditions
- Neoplasms
- Registration Number
- KCT0007015
- Lead Sponsor
- Seoul National University Bundang Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
Patients who received immunochemotherapy containing high-dose methrexate and rituximab of 2 to 6 cycles as a induction therapy, and had a partial response (PR) or better, but can not undergo autologous hematopoietic stem cell transplantation or whole brain radiotherapy as a consolidation therapy
Exclusion Criteria
Patients who are scheduled to undergo autologous hematopoietic stem cell transplantation or whole brain radiotherapy after high-dose methrexate-based immunochemical therapy.
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival rate at 2 years
- Secondary Outcome Measures
Name Time Method Overall response rate, overall survival rate, adverse events